HRG and breast cancer: Nonetheless, HRG/HER2:HER3-induced autocrine secretion of IL-8 can be viewed as part of the endocrine resistance program in HRG-overexpressing ER+ breast cancer cells by controlling the magnitude of the estrogen response and mediating the anti-estrogen inhibition of ERα [57].